Impact of clopidogrel treatment on platelet function and thrombogenecity in diabetic patients undergoing elective coronary stenting

Anand Singla, Kevin P. Bliden, Young-Hoon Jeong, Joseph DiChiara, Mark J. Antonino, Denny P. Mathew, William C. Muse, Katrina Abadilla, Tania Gesheff, Udaya S. Tantry, Paul A. Gurbel

Sinai Center for Thrombosis Research, Baltimore, USA.

DOI: 10.4236/jdm.2012.22025                

Abstract

High platelet reactivity (HPR) and suboptimal response to dual antiplatelet therapy (DAPT) may explain high recurrent rates of ischemic events in Type II diabetes mellitus (DM) patients undergoing percutaneous coronary intervention (PCI). The aim of this study was to examine the effect of clopidogrel on platelet reactivity, and thrombogenecity between DM and non-DM PCI-treated patients (n = 138). Patients were categorized according to clopidogrel treatment and DM status. Patients received a maintenance-dose clopidogrel of 75 mg/d (C75 group, n = 72) or a 600 mg clopidogrel loading-dose in clopidogrel na?ve patients (C600 group, n = 66). Platelet function was assessed by thrombelastography, flow cytometry, VerifyNow^TM aspirin assay and light transmittance aggregometry (LTA). Aspirin response was similar between treatments and DM status. In the C75 group, DM patients had higher 5 and 20 μM ADP-, 2 μg/ml collagen-induced LTA; and p-selectin expression compared to non-DM patients (p ≤ 0.05 for all). DM patients in the C600 group had higher 5 and 20 μM ADP-induced LTA post dosing (p < 0.04) and higher maximum induced platelet-fibrin clot strength at baseline and post dosing timepoints (p < 0.05 for all). The present study provides further evidence that DM patients on DAPT are characterized by persistently higher platelet reactivity and thrombogenecity, making them potential candidates for more potent P2Y₁₂ receptor antagonists.

Keywords

Diabetes; Clopidogrel; Platelet Reactivity; Hypercoagulability

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Natali, A., Vichi, S., Landi, P., et al. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. The New England Journal of Medicine, 339, 229-234. doi:10.1056/NEJM199807233390404
[2]	Stein, B., Weintraub, W.S., Gebhart, S.P., et al. (1995) Influence of diabetes mellitus on early and late outcome after percutaneous coronary angioplasty. Circulation, 9, 979-989.
[3]	Abizaid, A., Kornowski, R., Mintz, G.S., et al. (1998) The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. Journal of the American College of Cardiology, 32, 584-589. doi:10.1016/S0735-1097(98)00286-1
[4]	King, S.B. 3rd, Smith, S.C. Jr., Hirshfeld, J.W. Jr., Feldman, T.E., Kern, M.J., O’Neill, W.W., et al. (2008) 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association task force on practice guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 Writing Committee. Circulatio
[5]	Wright, R.S., Anderson, J.L., Adams, C.D., et al. (2011) 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/ non-st-elevation myocardial infarction (updating the 2007 guideline): A report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation, 123, 2022-2060. doi:10.1161/CIR.0b013e31820f2f3e
[6]	De Luca, G., Sauro, R., Varricchio, A., et al. (2010) Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIbIIIa inhibitors and BMS or DES. Journal of the Thrombosis and Thrombolysis, 30, 133-141. doi:10.1007/s11239-009-0420-5
[7]	Angiolillo, D.J., Bernardo, E., Sabaté, M., et al. (2007) Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American College of Cardiology, 50, 1541-1547. doi:10.1016/j.jacc.2007.05.049
[8]	Hess, K. and Grant, P.J. (2011) Inflammation and thrombosis in diabetes. Thrombosis and Haemostasis, 105, S43-S54. doi:10.1160/THS10-11-0739
[9]	Morel, O., Kessler, L., Ohlmann, P. and Bareiss, P. (2010) Diabetes and the platelet: Toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis, 212, 367-376. doi:10.1016/j.atherosclerosis.2010.03.019
[10]	DiChiara, J., Bliden, K.P., Tantry, U.S., et al. (2007) The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: An analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes, 56, 3014-3019. doi:10.2337/db07-0707
[11]	Bhatt, D.L., Marso, S.P., Hirsch, A.T., et al. (2002) Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. The American Journal of Cardiology, 15, 625-628. doi:10.1016/S0002-9149(02)02567-5
[12]	Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., et al. (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes, 54, 2430-2435. doi:10.2337/diabetes.54.8.2430
[13]	Gurbel, P.A., Bliden, K.P., Hayes, K.M., et al. (2005) The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. Journal of the American College of Cardiology, 45, 1392-1396. doi:10.1016/j.jacc.2005.01.030
[14]	Gurbel, P.A., Bliden, K.P., Navickas, I.A., et al. (2010) Adenosine diphosphate-induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic events. American Heart Journal, 160, 346-354. doi:10.1016/j.ahj.2010.05.034
[15]	Gurbel, P.A., Bliden, K.P., Saucedo, J.F., et al. (2009) Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: Effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction: Results of the clear platelets-2 (clopidogrel with eptifibatide to arrest the reactivity of platelets) study. Journal of the American College of Cardiology, 53, 648-657. doi:10.1016/j.jacc.2008.10.045
[16]	Rivard, G.E., Brummel-Ziedins, K.E., Mann, K.G., et al. (2005) Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. Journal of Thrombosis and Haemostasis, 3, 2039-2043. doi:10.1111/j.1538-7836.2005.01513.x
[17]	Alberti, K.G. and Zimmet, P.Z. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Medicine, 15, 539-553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
[18]	Bliden, K.P., Tantry, U., Zaman, K., et al. (2005) High platelet reactivity is a risk factor for post-discharge ischemic complications following elective coronary stenting. Journal of American College of Cardiology, 47, 45B.
[19]	Gum, P.A., Kottke-Marchant, K., Welsh, P.A., White, J. and Topol, E.J. (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. Journal of the American College of Cardiology, 41, 961-965. doi:10.1016/S0735-1097(02)03014-0
[20]	Ferreiro, J.L. and Angiolillo, D.J. (2011) Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation, 123, 798-813. doi:10.1161/CIRCULATIONAHA.109.913376
[21]	Geisler, T., Anders, N., Paterok, M., et al. (2007) Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care, 30, 372-374. doi:10.2337/dc06-1625
[22]	Anfossi, G., Russo, I. and Trovati, M. (2008) Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. Current Vascular Pharmacology, 6, 313-328. doi:10.2174/157016108785909760
[23]	Ferreira, I.A., Mocking, A.I., Feijge, M.A., et al. (2006) Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arteriosclerosis Thrombosis and Vascular Biology, 26, 417-422. doi:10.1161/01.ATV.0000199519.37089.a0
[24]	Colwell, J.A. and Nesto, R.W. (2003) The platelet in diabetes: Focus on prevention of ischemic events. Diabetes Care, 26, 2181-2188. doi:10.2337/diacare.26.7.2181
[25]	Schneider, D.J. (2009) Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care, 32, 525-527. doi:10.2337/dc08-1865
[26]	Ferreira, I.A., Eybrechts, K.L., Mocking, A.I., Kroner, C. and Akkerman, J.W. (2004) IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. The Journal of Biological Chemistry, 279, 3254-3264. doi:10.1074/jbc.M305474200
[27]	Erlinge, D., Varenhorst, C., Braun, O.O., et al. (2008) Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. Journal of the American College of Cardiology, 52, 1968-1977. doi:10.1016/j.jacc.2008.07.068
[28]	Hoyo-Vadillo, C., Garcia-Mena, J., Valladares, A., et al. (2010) Association of CYP2C19 genotype with type 2 diabetes. Health, 10, 1184-1190. doi:10.4236/health.2010.210174
[29]	Abell, L.M. and Liu, E.C. (2011) Dissecting the activation of thienopyridines by cytochrome P450’s using a pharmacodynamic assay in vitro. The Journal of Pharmacology and Experimental Therapeutics, 339, 589-596. doi:10.1124/jpet.111.184895
[30]	Mega, J.L., Close, S.L., Wiviott, S.D., et al. (2009) Cytochrome P-450 polymorphisms and response to clopidogrel. The New England Journal of Medicine, 360, 354-362. doi:10.1056/NEJMoa0809171
[31]	Angiolillo, D.J., Shoemaker, S.B., Desai, B., et al. (2007) A randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimus (optimizing anti-platelet therapy in diabetes MellitUS) study. Circulation, 115, 708-716. doi:10.1161/CIRCULATIONAHA.106.667741
[32]	Angiolillo, D.J., Capranzano, P., Goto, S., et al. (2008) A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the Optimus-2 study. European Heart Journal, 29, 2202-2211. doi:10.1093/eurheartj/ehn287
[33]	Angiolillo, D.J., Badimon, J.J., Saucedo, J.F., et al. (2011) Pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: Results of the optimizing anti-platelet therapy in diabetes MellitUS (Optimus)-3 Trial. European Heart Journal, 32, 838-846. doi:10.1093/eurheartj/ehq494
[34]	Han, Y., Li, Y., Wang, S., et al. (2009) Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study. American Heart Journal, 157, 733-739. doi:10.1016/j.ahj.2009.01.006
[35]	Wiviott, S.D., Braunwald, E., Angiolillo, D.J., et al. (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in Myocardial Infarction 38. Circulation, 118, 1626-1636. doi:10.1161/CIRCULATIONAHA.108.791061
[36]	Manoukian, S.V. (2009) Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. The American Journal of Cardiology, 104, 9C-15C. doi:10.1016/j.amjcard.2009.06.020
[37]	El Ghannudi, S., Ohlmann, P., Jesel, L., et al. (2011) Impaired inhibition of P2Y12 by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention. Atherosclerosis, 217, 465-472. doi:10.1016/j.atherosclerosis.2011.03.039
[38]	Mangiacapra, F., Patti, G., Peace, A., et al. (2010) Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. The American Journal of Cardiology, 106, 619-623. doi:10.1016/j.amjcard.2010.04.015
[39]	Tantry, U.S., Bliden, K.P., Suarez, T.A., et al. (2010) Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: Results of the Thrombotic RIsk Progression (TRIP) study. Platelets, 21, 360-367. doi:10.3109/09537100903548903
[40]	Tantry, U.S. and Gurbel, P.A. (2011) Assessment of oral antithrombotic therapy by platelet function testing. National Reviews Cardiology, 8, 572-579. doi:10.1038/nrcardio.2011.107
[41]	Feuring, M., Wehling, M., Burkhardt, H. and Schultz, A. (2010) Coagulation status in coronary artery disease patients with type II diabetes mellitus compared with nondiabetic coronary artery disease patients using the PFA-100? and ROTEM?. Platelets, 21, 616-622. doi:10.3109/09537104.2010.504868
[42]	Stellbaum, C., Willich, T., Boltzen, U., et al. (2007) Clopidogrel-mediated reduction of circulating tissue factor in patients with stable coronary artery disease. European Journal of Haematology, 78, 347-352. doi:10.1111/j.1600-0609.2007.00820.x
[43]	Zhao, L., Gray, L., Leonardi-Bee, J., et al. (2006) Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets, 17, 100-104. doi:10.1080/09537100500235966
[44]	Geisler, T., Mueller, K., Aichele, S., et al. (2010) Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: Prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clinical Research in Cardiology, 99, 743-752. doi:10.1007/s00392-010-0179-x
[45]	Muhlestein, J.B. (2010) Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thrombosis and Haemostasis, 103, 71-82. doi:10.1160/TH09-03-0177
[46]	Antonino, M.J., Mahla, E., Bliden, K.P., Tantry, U.S. and Gurbel, P.A. (2009) Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. The American Journal of Cardiology, 103, 1546-1550. doi:10.1016/j.amjcard.2009.01.367
[47]	Collet, J.P., Silvain, J., Landivier, A., et al. (2008) Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: The reload with clopidogrel before coronary angioplasty in subjects treated long term with dual antiplatelet therapy (reload) study. Circulation, 118, 1225-1233. doi:10.1161/CIRCULATIONAHA.108.776757
[48]	Di Sciascio, G., Patti, G., Pasceri, V., et al. (2010) Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: Results of the Armyda-4 reload (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized trial. European Heart Journal, 31, 1337-1343. doi:10.1093/eurheartj/ehq081